Clareo Health | Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study
Role of Triggering Receptor Expressed on Myeloid Cells (TREM-1) as a Novel Biomarker in Human Epidermal Growth Factor Receptor -2 (HER-2) Negative Breast Cancer: a Molecular and Clinical Study
a prospective observational cohort study on the role of TREM-1 as a novel immune biomarker in HER-2 breast cancer it's a molecular and clinical study. our aim is to assess prognostic significance of TREM-1 expression at baseline and post neo-adjuvant treatment regards DFS \& OS and to quantify TREM-1 expression and correlate its level with clinical and pathological response to neo-adjuvant treatment. and evaluate its association with immune cells (eg. monocytes and neutrophils)
Age
18–80
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
female patient aged \< 18 yrs. old
histological proven breast cancer
HER-2 negative (hormonal positive or triple negative)
planned to receive neo-adjuvant therapy
complete clinical, radiological and therapeutic data
You may not be if
metastatic breast cancer
HER-2 positive
incomplete clinical, radiological or therapeutic data
